Literature DB >> 17497102

[Prophylactic and therapeutic HPV immunization].

M Müller1, L Gissmann.   

Abstract

Papilloma viruses (PV) have been known to cause benign and malignant tumors in animals for more than 100 years. It took over 20 years to win general acceptance for their causative role in anogenital carcinomas in humans in particular in cervial carcinoma. Extensive research has led to the development of a prophylactic vaccine which is now commercially available. It remains to be investigated if HPV-specific therapeutic vaccines can be developed.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17497102     DOI： 10.1007/s00105-007-1346-5

Source DB:  PubMed          Journal:  Hautarzt        ISSN： 0017-8470            Impact factor:   0.751


  56 in total

1.  TUMORIGENIC NUCLEIC ACID EXTRACTS FROM TISSUES OF A TRANSPLANTABLE CARCINOMA, VX7.

Authors:  Y ITO; C A EVANS
Journal:  J Natl Cancer Inst       Date:  1965-03       Impact factor: 13.506

2.  Carcinoma of the cervix in nulliparous and celibate women.

Authors:  J E TOWNE
Journal:  Am J Obstet Gynecol       Date:  1955-03       Impact factor: 8.661

3.  A vaccination procedure which increases the frequency of regressions of Shope papillomas of rabbits.

Authors:  C A EVANS; L R GORMAN; Y ITO; R S WEISER
Journal:  Nature       Date:  1962-01-20       Impact factor: 49.962

Review 4.  Papillomavirus-like particle vaccines.

Authors:  J T Schiller; D R Lowy
Journal:  J Natl Cancer Inst Monogr       Date:  2001

5.  Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization.

Authors:  R Kirnbauer; L M Chandrachud; B W O'Neil; E R Wagner; G J Grindlay; A Armstrong; G M McGarvie; J T Schiller; D R Lowy; M S Campo
Journal:  Virology       Date:  1996-05-01       Impact factor: 3.616

6.  Laboratory production in vivo of infectious human papillomavirus type 11.

Authors:  J W Kreider; M K Howett; A E Leure-Dupree; R J Zaino; J A Weber
Journal:  J Virol       Date:  1987-02       Impact factor: 5.103

7.  Studies on vaccination against papillomaviruses: the immunity after infection and vaccination with bovine papillomaviruses of different types.

Authors:  W F Jarrett; B W O'Neil; J M Gaukroger; K T Smith; H M Laird; M S Campo
Journal:  Vet Rec       Date:  1990-05-12       Impact factor: 2.695

8.  Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccine.

Authors:  Rebecca T Emeny; Cosette M Wheeler; Kathrin U Jansen; William C Hunt; Tong-Ming Fu; Judith F Smith; Stefani MacMullen; Mark T Esser; Xavier Paliard
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

9.  Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera.

Authors:  R C Rose; R C Reichman; W Bonnez
Journal:  J Gen Virol       Date:  1994-08       Impact factor: 3.891

10.  Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection.

Authors:  F Breitburd; R Kirnbauer; N L Hubbert; B Nonnenmacher; C Trin-Dinh-Desmarquet; G Orth; J T Schiller; D R Lowy
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103
View more
  1 in total

Review 1.  [Differential diagnosis of condylomata acuminata. Indication for histopathology].

Authors:  G Gross
Journal:  Hautarzt       Date:  2009-06       Impact factor: 0.751
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.